Chronic myeloid leukemia (CML) is a hematopoietic disease characterized by expansion of myeloid blood cells. It is caused by the t(9;22) chromosomal translocation that results in the expression of the fusion tyrosine kinase BCR-ABL. Tyrosine kinase inhibitor (TKI) therapy has led to long-term remissions, but patients remain BCR-ABL+. There is agreement that TKIs do not kill CML stem cells; however, it is controversial whether this is because of a lack of BCR-ABL kinase inhibition in CML stem cells or because CML stem cells do not require BCR-ABL for survival. In this issue of the JCI, Corbin and colleagues provide definitive evidence that BCR-ABL is kinase active in CML stem cells and that TKIs inhibit this kinase activity without affecting CML stem cell survival. Rather, CML stem cells revert to a normal dependence on cytokines for survival and proliferation. These results demonstrate that the CML stem cell is not BCR-ABL addicted and have important implications for developing curative therapeutic approaches to CML.
Alexander Perl, Martin Carroll
Title and authors | Publication | Year |
---|---|---|
One more stem cell niche: how the sensitivity of chronic myeloid leukemia cells to imatinib mesylate is modulated within a "hypoxic" environment
PD Sbarba, E Rovida, I Marzi, MG Cipolleschi |
Hypoxia | 2014 |
Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro
L Wu, Y Wu, R Chen, Y Liu, L Huang, L Lou, Z Zheng, Y Chen, J Xu |
Acta Pharmacologica Sinica | 2014 |
The metabolically-modulated stem cell niche: a dynamic scenario regulating cancer cell phenotype and resistance to therapy
E Rovida, S Peppicelli, S Bono, F Bianchini, I Tusa, G Cheloni, I Marzi, MG Cipolleschi, L Calorini, PD Sbarba |
Cell cycle (Georgetown, Tex.) | 2014 |
Phosphatase of regenerating liver in hematopoietic stem cells and hematological malignancies
M Kobayashi, S Chen, R Gao, Y Bai, ZY Zhang, Y Liu |
Cell cycle (Georgetown, Tex.) | 2014 |